towards social isolation, with neglect of self-care and daily routines, and a deleterious substance consumption of up to 2 l of coke/day and 40 cigarettes/day. This was accompanied by subjective complaints of drowsiness, so that treatment was changed to aripiprazole 15 mg/day.
Since then, the patient has been under our treatment in the Mental Health Therapeutic Community. Here, despite the reduction in the consumption of harmful substances, episodes of intense distress were evident in addition to firstand second-phase insomnia, and therefore we added asenapine 5 mg/day to the treatment. Since then there has been significant clinical improvement in the patient, as the anxiety episodes were associated with the regularisation of the sleep-wake rhythm. The DASS 21 (Depression Anxiety Stress Scales) score for anxiety was 19 points (extremely severe anxiety) before the introduction of asenapine 5 mg/day and 5 points (mild anxiety) 2 weeks after the introduction of asenapine.
Therefore, we consider it noteworthy that even in generally recommended antipsychotic monotherapy there are certain molecules that can be useful in the treatment of other associated symptoms.
The potential anxiolytic effect of asenapine with demonstrated potential antipsychotic efficacy without risk of abuse (as occurs with benzodiazepines) makes it an option in the therapeutic management of psychotic anxiety.
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